CO2021003460A2 - El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión - Google Patents

El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión

Info

Publication number
CO2021003460A2
CO2021003460A2 CONC2021/0003460A CO2021003460A CO2021003460A2 CO 2021003460 A2 CO2021003460 A2 CO 2021003460A2 CO 2021003460 A CO2021003460 A CO 2021003460A CO 2021003460 A2 CO2021003460 A2 CO 2021003460A2
Authority
CO
Colombia
Prior art keywords
alpha
adrenergic receptor
improve vision
receptor agonists
visual
Prior art date
Application number
CONC2021/0003460A
Other languages
English (en)
Spanish (es)
Inventor
Mohammed Dibas
Daniel W Gil
Wayne Chen
Miguel Alcantara
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO2021003460A2 publication Critical patent/CO2021003460A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2021/0003460A 2018-08-21 2021-03-17 El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión CO2021003460A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (1)

Publication Number Publication Date
CO2021003460A2 true CO2021003460A2 (es) 2021-04-08

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003460A CO2021003460A2 (es) 2018-08-21 2021-03-17 El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
WO2020041340A1 (en) 2020-02-27
JP2021534217A (ja) 2021-12-09
BR112021003295A2 (pt) 2021-05-18
AU2019325486A1 (en) 2021-03-25
KR20210047323A (ko) 2021-04-29
AR115991A1 (es) 2021-03-17
EP3840750A1 (en) 2021-06-30
MX2021002112A (es) 2021-07-16
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
PH12021550372A1 (en) 2021-11-29
IL280990A (en) 2021-04-29
US20240358682A1 (en) 2024-10-31
US20210205273A1 (en) 2021-07-08
CN112823003A (zh) 2021-05-18
CA3110318A1 (en) 2020-02-27
CL2021000440A1 (es) 2021-09-20
TW202021584A (zh) 2020-06-16
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021003460A2 (es) El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión
MX2021015850A (es) Agonista beta adrenergico y metodos de uso del mismo.
ECSP20013332A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
ECSP21077614A (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
MX374501B (es) Formulaciones de anticuerpos de her2 subcutáneas.
CL2018000101A1 (es) Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MX2018014869A (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
DOP2020000039A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
UY35258A (es) ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
EA201791005A1 (ru) Улучшенные антитела против il-6
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
CL2014002918A1 (es) Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras.
MX2022015854A (es) Sistemas y metodos para mitigar la interferencia dentro del espectro usado activamente.
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
AR115790A1 (es) Apirasas solubilizadas, métodos y usos